Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Long-Term Results After Drug-Eluting Versus Bare-Metal Stent Implantation in Saphenous Vein Grafts: Randomized Controlled Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Duration of early systolic lengthening: prognostic potential in the general population

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Association between regional longitudinal strain and left ventricular thrombus formation following acute myocardial infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. A Validated Echocardiographic Risk Model for Predicting Outcome Following ST-segment Elevation Myocardial Infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Coronary CT Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
The use of the glycoprotein (GP) IIb/IIIa receptor antagonist Abciximab has over the years become an important part of the anticoagulant regimen in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Abciximab is a potent inhibitor of platelet aggregation and thrombus formation, but other mechanisms, such as suppression of the inflammatory pathways, have also been proposed to contribute to the benefits of Abciximab.The optimal route of administration, i.e. intravenous versus intracoronary, of the first dose has been questioned, but only tested in small, non-randomised and retrospective studies or studies with short follow-up. No definite conclusion can be made based on these studies.In this review we present the current knowledge published about the intracoronary administration of Abciximab including the mechanisms behind the potential beneficial effects, and the safety. The emphasis will be on clinical trials rather than on studies on the pharmacological mechanisms, as the latter have been reviewed thoroughly elsewhere.Our conclusion from this present review is that randomized trials of intracoronary versus intravenous bolus of Abciximab are needed.
Original languageEnglish
JournalCurrent Cardiology Reviews
Volume4
Issue number4
Pages (from-to)293-9
Number of pages7
ISSN1573-403X
DOIs
Publication statusPublished - 1 Nov 2008

ID: 32174952